Skip to main
RNXT

RenovoRx (RNXT) Stock Forecast & Price Target

RenovoRx (RNXT) Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

RenovoRx is a clinical-stage biopharmaceutical company that is making significant progress in its clinical drug development and RenovoCath commercialization, indicating strong potential for revenue growth. The recent positive 2nd interim analysis of its Phase III TIGeR-PaC trial and the increasing number of active commercial cancer centers also add to the company's positive outlook. The large market potential for its lead therapy candidate RenovoGem and key milestones expected to be reached in June 2026 and 2027 further solidify the company's promising future. With a strong balance sheet and a new CFO in place, RenovoRx is on track for success and presents high rewards for the risks involved.

Bears say

RenovoRx is a clinical-stage biopharmaceutical company with a promising patented Trans-Arterial Micro-Perfusion therapy platform. However, its current valuation may be overstated due to significant risks including balance sheet/liquidity risks and failure to gain regulatory approvals. The recent appointment of a new CFO and plans to expand to 36 active commercial cancer centers may contribute to potential revenue growth but may not be enough to offset these risks and lead to significant upside for investors. Additionally, the company's focus on local drug delivery carries high risks but may lead to improved therapeutic outcomes for cancer patients.

RenovoRx (RNXT) has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of RenovoRx and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About RenovoRx (RNXT) Forecast

Analysts have given RenovoRx (RNXT) a Strong Buy based on their latest research and market trends.

According to 2 analysts, RenovoRx (RNXT) has a Strong Buy consensus rating as of Aug 29, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8.75, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8.75, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

RenovoRx (RNXT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.